Pharma giant pays hefty premium for biotech firm to get into growing RNAi market.
|
Investors send the RNAi company’s stock down on news of follow-on offering.
|
The drug maker plans to work with Alnylam Pharmaceuticals to combat pandemic flu.
|
The CEO of Sirna Therapeutics discusses the first human trials of a drug candidate based on breakthrough RNAi technology.
|
Drug maker will work with Alnylam Pharmaceuticals on a multiyear gene therapy alliance.
|
AMO snaps up Quest; Sirna takes RNAi through Phase I; Bayhill raises $35.4 million; Glaxo’s vaccine approved.
|
OncoGeneX is using a decades-old technology to devise a new class of drugs.
|
After the hype, and then the lull, biotechs are making progress in pushing RNAi therapies into real-world treatments and real-deal revenues.
|
The struggling RNAi market just got a lot more interesting.
|